The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol- 13-acetate activation of the multidrug resistance-1 promoter

Cell Growth and Differentiation

Volumn 10, Issue 6, 1999, Pages 377-386

  McCoy, Candice ^a,b   McGee, Sara B ^b   Cornwell, Marilyn M ^b  

^a AMGEN INC   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; LUCIFERASE; MULTIDRUG RESISTANCE PROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE; UNCLASSIFIED DRUG; WILMS TUMOR SUPPRESSOR PROTEIN; ZINC FINGER PROTEIN;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEMATOPOIESIS; HUMAN; HUMAN CELL; NEPHROBLASTOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SEQUENCE HOMOLOGY;

DNA-BINDING PROTEINS; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, WILMS TUMOR; HUMANS; IMMEDIATE-EARLY PROTEINS; K562 CELLS; P-GLYCOPROTEIN; PROMOTER REGIONS (GENETICS); TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTORS; WILMS TUMOR; WT1 PROTEINS; ZINC FINGERS;

EID: 0033021651     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Kane, S. E. Multidrug resistance of cancer cells. In: B. Testa and U. A. Meyer (eds.), Advances in Drug Research, pp. 182-252. New York: Academic Press, 1996.
2. Gottesman, M. M., Ambudkar, S. V., Cornwell, M. M., Pastan, I., and Germann, U. A. Multidrug resistance transporter. In: S. Schultz, T. Andrioll, A. Brown, D. Fambrough, F. Hoffman, and M. Welsh (eds.), Molecular Biology of Membrane Transport Disorders, pp. 243-257. New York: Plenum Publishing Corp., 1996.
3. Nooter, K., and Sonneveld, P. Clinical relevance of P-glycoprotein expression in haematological malignancies. Leuk. Res., 18: 233-243, 1994.
4. Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S. L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G. M., Lieber, M., Cossman, J., Gottesman, M. M., and Pastan, I. Expression of a multidrug resistance gene In human cancers. J. Natl. Cancer Inst., 81: 116-124, 1989.
5. Sato, H., Gottesman, M. M., Goldstein, L. J., Pastan, I., Block, A. M., Sandberg, A. A., and Preisler, H. D. Expression of the multidrug resistance gene in myeloid leukemias. Leuk. Res., 14: 11-21, 1990.
6. Musto, P., Mellillo, L., Lombardi, G., Matera, R., Di Giorgio, G., and Carotenuto, M. High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br. J. Haematol., 77: 50-53, 1991.
7. Zhou, D. C., Marie, J. P., Suberville, A. M., and Zittoun, R. Relevance of mdr1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia (Baltimore), 6: 879-885, 1992.
8. Campos, L,. Guyotat, D., Archimbaud, E., Calmard-Oriol, P., Tsuruo, T., Troncy, J., Treille, D., and Riere, D. Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphoblastic leukemia cells at diagnosis. Blood, 79: 473-476, 1992.
9. Michieli, M., Damiani, D., Geromin, A., Michelutti, A., Fanin, R., Raspadori, D., Ruso, D., Visani, G., Dinota, A., Pileri, S.,Tsuruo, T., Grandi, M., Baccarani, M., and Tura, S. Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia. Eur. J. Haematol., 48: 87-92, 1992.
10. Del Poeta, G., Stase, R., Venditti, A., Suppo, G., Aronica, G., Bruno, A., Masi, M., Tabilio, A., and Papa, G. Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia (Baltimore), 8: 388-394, 1994.
11. Wood, P. Burgess, R., MacGregor, A., and Yin, J. A. L P-glycoprotein expression on acute myeloid leukemia blast cells at diagnosis predicts response to chemotherapy and survival. Br. J. Haematol., 87: 509-514, 1994.
12. Zochbauer, S., Gsur, A., Brunner, R., Kryle, P. A., Lechner, K., and Pirker, R. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia (Baltimore), 8: 974-977, 1994.
13. Leith, C. P., Kopecky, K. J., Godwin, J., McConnell, T., Slovak, M. L., Chen, I. M., Head, D. R., Appelbaum, F. R., and Willman, C. L. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood, 89: 3323-3329, 1997.
14. Schinkel, A. H., Smit, J. J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A., van der Valk, M. A., Robanus-Maandag, E. C., and te Riele, H. P. Disruption of the mouse mdra P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 77: 491-502, 1994.
15. Smit, J. J. M., Schinkel, A. H., and Oude Elferink, R. P. J. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell, 75: 451-462, 1993.
16. van Helvoort, A., Smith, A. J., Sprong, H., Fritzsche, I., Schinkel, A. H., Borst, P., and van Meer, G. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell, 87: 507-517, 1996.
17. Chaudhary, P. M., and Roninson, I. B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell, 66: 85-94, 1991.
18. Chaudhary, P. M., and Roninson, I. B. Expression and activity of the multidrug resistance P-glycoprotein pump in human peripheral blood lymphocytes. Blood, 80: 2735-2739, 1992.
19. Drach, D., Zhao, S., Drack, J., Mahadevia, R., Gattringer, C., Huber, H., and Andreef, M. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistance phenotype. Blood, 80: 2729-2734, 1992.
20. Klimecki, W. T., Futscher, B. W., Grogan, T. M., and Dalton, W. S. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood, 83: 2451-2458, 1994.
21. Gupta, S., Kim, C. H., Tsuruo, T., and Gollapudi, S. Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: a role in cytotoxic effector function. J. Clin. Immunol., 12: 451-458, 1992.
22. Chong, A. S-F., Markham, P. N., Gebel, H. M., Bines, S. D., and Coon, J. S. Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural kill cells. Cancer Immunol. Immunother., 36: 133-139, 1993.
23. Markham, P. N., Coon, J. S., Chong, A. S-F., and Gebel, H. M. Natural killer cell cytotoxicity and the multidrug resistance gene. Transplant. Proc., 25: 96-97, 1993.
24. Chaudhary, P. M., and Roninson, I. M. Activation of MDR1 by protein kinase C agonists. Oncogene Res., 4: 281-290, 1992.
25. McCoy, C., Smith, D. S., and Cornwell, M. M. 12-O-Tetradecanoylphorbol-13-acetate activation of the MDR1 promoter is mediated by EGR. Mol. Cell. Biol., 15: 6100-6108, 1995.
26. Sukhatme, V. P. Early transcriptional events in cell growth: the EGR family. J. Am. Soc. Nephrol., 1: 859-866, 1990.
27. Madden, S. L., and Rauscher, F. J., III. Positive and negative regulation of transcription and cell growth mediated by the EGR family of zinc-finger gene products. Ann. NY Acad. Sci., 684: 75-84, 1993.
28. Christy, B., and Nathans, D. DNA binding site of the growth factor-inducible protein Zif268. Proc. Natl. Acad. Sci. USA, 86: 8737-8741, 1989.
29. Lemaire, P., Vesque, C., Schmitt, J., Stunnenberg, H., Frank, R., and Charnay, P. The serum-inducible mouse gene Krox-24 encodes a sequence-specific transcriptional activator. Mol. Cell. Biol., 10: 3456-3467, 1990.
30. Molnar, G., Crozat, A., and Pardee, A. B. The immediate-early gene EGR1-1 regulates the activity of the thymidine kinase promoter at the G0-to-G1 transition of the cell cycle. Mol. Cell. Biol., 14: 5242-5248, 1994.
31. Pospelov, V. A., Pospelova, T. V., and Julien, J. AP-1 and Krox-24 transcription factors activate the neurofilament light gene promoter in P19 embryonal carcinoma cells. Cell Growth Differ., 5: 187-196, 1994.
32. Maltzman, J. S., Carman, J. A., and Monroe, J. G. Role of EGR1 in regulation of stimulus-dependent CD44 transcription in B lymphocytes. Mol. Cell. Biol., 16: 2283-2294, 1996.
33. Bickmore, W. A., Oghene, K., Little, M. H., Seawright, A., van Heyningen, V., and Hastie, N. D. Modulation of DNA binding specificity by alternative splicing of the Wilms tumor wt1 gene transcript. Science (Washington DC), 257: 235-237, 1992.
34. Wang, Z-Y., Qiu, Q-Q., Enger, K. T., and Deuel, T. F. A second transcriptionally active DNA-binding site for the Wilms' tumor gene product, WT1. Proc. Natl. Acad. Sci. USA, 90: 8896-8900, 1993.
35. Fraizer, G. C., Wu, Y-J., Hewitt, S. M., Maity, T., Ton, C. C. T., Huff, V., and Saunders, G. F. Transcriptional regulation of the human Wilms' tumor gene (WT1). Cell-type specific enhancer and promiscuous promoter. J. Biol. Chem., 269: 8892-8900, 1994.
36. Nakagama, H., Heinrich, G., Pelletier, J., and Housman, D. Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product. Mol. Cell. Biol., 15: 1489-1498, 1995.
37. Gashler, A. L., Swaminathan, S., and Sukhatme, V. P. A novel repression module, an extensive activation domain, and a bipartite nuclear localization signal defined in the immediate-early transcription factor EGR-1. Mol. Cell. Biol., 13: 4556-4571, 1993.
38. Wang, Z-Y., Qiu, Q-Q., and Deuel, T. F. The Wilms' tumor gene product WT1 activates or suppresses transcription through separate functional domains. J. Biol. Chem., 268: 9172-9175, 1993.
39. Drummond, I. A., Madden, S. L., Rohwer-Nutter, P., Bell, G. I., Sukhatme, V. P., and Rauscher, F. J., III. Repression of the insulin-like growth factor II gene by the Wilms' tumor suppressor WT1. Science (Washington DC), 257: 674-677, 1992.
40. Gashler, A. L., Bonthron, D. T., Madden, S. L., Rauscher, F. J., III, Collins, T., and Sukhatme, V. P. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms' tumor suppressor WT1. Proc. Natl. Acad. Sci. USA, 89: 10984-10988, 1992.
41. Wang, Z. Y., Madden, S. L., Deuel, T. F., and Rauscher, F. J., III. The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene. J. Biol. Chem., 267: 21999-22002, 1992.
42. Werner, H., Re, G. G., Drummond, I. A., Sukhatme, V. P., Rauscher, F. J., III, Sens, D. A., Garvin, A. J., LeRoith, D., and Roberts, C. T., Jr. Increased expression of the insulin-like growth factor-l-receptor gene, IGFIR, in Wilms' tumor is correlated with modulation of IGFIR promoter activity by the Wilms' tumor gene product. Proc. Natl. Acad. Sci. USA, 90: 5828-5832, 1993.
43. Harrington, M. A., Konicek, B., Song, A., Xia, X-L., Fredericks, W. J., and Rauscher, F. J., III. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. J. Biol. Chem., 268: 21271-21275, 1993.
44. Dey, B. R., Sukhatme, V. P., Roberts, A. B., Sporn, M. B., Rauscher, F. J., III, and Kim, S-J. Repression of the transforming growth factor-β1 gene by the Wilms' tumor suppressor WT1 gene product. Mol. Endocrinol., 8: 595-602, 1994.
45. McCann, S., Sullivan, J., Guerra, J., Arcinas, M., and Boxer, L. M. Repression of the c-myb gene by WT1 protein in T and B cell lines. J. Biol. Chem., 270: 23785-23789, 1995.
46. Hewitt, S. M., Hamada, S., McDonnell, T. J., Rauscher, F. J., III, and Saunders, G. F. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res., 55: 5386-5389, 1995.
47. Martinerie, C., Chevalier, G., Rauscher, F. J., III, and Perbal, B. Regulation of nov by WT1: a potential role for nov in nephrogenesis. Oncogene, 12: 1479-1492, 1996.
48. Adachi, Y., Matsubara, S., Pedraza, C., Ozawa, M., Tsutsui, J., Takamatsu, H., Noguchi, H., Akiyama, T., and Muramatsu, Y. Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1). Oncogene, 13: 2197-2203, 1996.
49. Moshier, J. A., Skunca, M., Wu, W., Boppana, S. M., Rauscher, F. J., III, and Dosescu, J. Regulation of omithine decarboxylase gene expression by the Wilms' tumor suppressor WT1. Nucleic Acids Res., 24: 1149-1157, 1996.
50. Varnum, B. C., Lim, R. W., Kujubu, D. A., Luner, S. J., Kaufman, S. E., Greenberger, J. S., Gasson, J. C., and Herschman, H. R. Granulocyte-macrophage colony-stimulating factor and tetradecanoyl phorbol acetate induce a distinct, restricted subset of primary-response TIS genes in both proliferating and terminally differentiated myeloid cells. Mol. Cell. Biol., 9: 3580-3583, 1989.
51. Horie, M., and Broxmeyer, H. E. Involvement of immediate-early gene expression in the synergistic effects of steel factor in combination with granulocyte-macrophage colony-stimulating factor or interleukin-3 on proliferation of a human factor-dependent cell line. J. Biol. Chem., 268: 968-973, 1993.
52. Nguyen, H. Q., Hoffman-Liebermann, B., and Liebermann, D. A. The zinc finger transcription factor Egr-1 is essential for and restricts differentiation along the macrophage lineage. Cell, 72: 197-209, 1993.
53. Krishnaraju, K., Nguyen, H. Q., Liebermann, D. A., and Hoffman, B. The zinc finger transcription factor Egr-1 potentiates macrophage differentiation of hematopoietic cells. Mol. Cell. Biol., 15; 5499-5507, 1995.
54. Phelan, S. A., Lindberg, C., and Call, K. M. Wilms' tumor gene, WT1, mRNA is down-regulated during induction of erythroid and megakaryocytic differentiation of K562 cells. Cell Growth Differ., 5: 677-686, 1994.
55. Sekiya, M. Adachi, M., Hinoda, Y., Imai, K., and Yachi, A. Downregulation of Wilms' tumor gene (wt1) during myelomonocytic differentiation in HL60 cells. Blood, 83: 1876-1882, 1994.
56. Maurer, U. Brieger, J., Weidmann, E., Mitrou, P. S., Hoelzer, D., and Bergmann, L. The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Exp. Hematol., 25: 945-950, 1997.
57. Madden, S. L., Cook, D. M., Morris, J. F., Gashler, A., Sukhatme, V. P., and Rauscher, F. J., III. Transcriptional repression mediated by the WT1 Wilms' tumor gene product. Science (Washington DC), 253: 1550-1553, 1991.
58. Cook, D. M., Hinkes, M. T., Bemfield, M., and Rauscher, F. J., III. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1. Oncogene, 13: 1789-1799, 1996.
59. Wang, Z-Y., Qiu, Q-Q., Gurrieri, M., Huang, J., and Deuel, T. F. WT1, the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein. Oncogene, 10: 1243-1247, 1995.
60. Cornwell, M. M., and Smith, D. E. SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J. Biol. Chem., 268: 19505-19511, 1993.
61. Miltenberger, R. J., Farnham, P. J., Smith, D. E., Stommel, J. M., and Cornwell, M. M. v-Raf activates transcription of growth-responsive promoters via GC-rich sequences that bind the transcription factor SP1. Cell Growth Differ., 6: 549-556, 1995.
62. Wemer, H., Rauscher, F. J., III, Sukhatme, V. P., Drummond, I. A., Roberts, C. T., Jr., and LeRoith, D. Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site. J. Biol. Chem., 269: 12577-12582, 1994.
63. Maheswaran, S., Park, S., Bernard, A., Morris, J., Rauscher, F. J., III, Hill, D. E., and Haber, D. A. Physical and functional interaction between WT1 and p53 proteins. Proc. Natl. Acad. Sci. USA, 90: 5100-5104, 1993.
64. Johnstone, R. W., See, R. H., Sells, S. F., Wang, J., Muthukkumar, S., Englert, C., Haber, D. A., Licht, J. D., Sugrue, S. P., Roberts, T., Rangnekar, V. M., and Shi, Y. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol. Cell. Biol., 16: 6945-6956, 1996.
65. Wang, Z-Y., Qui, Q-Q., Seufert, W., Taguohi, T., Testa, F. R., Whitmore, S. A., Callen, D. F., Welsh, D., Shenk, T., and Deuel, T. F. Molecular cloning of the cDNA and chromosome localization of the gene for human ubiquitin-conjugating enzyme 9. J. Biol. Chem., 271: 24811-24816, 1996.
66. Ye, Y., Raychaudhuri, B., Gumey, A., Campbell, C. E., and Williams, B. R. G. Regulation of WT1 by phosphorylation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation. EMBO J., 15: 5606-5615, 1996.
67. Brieger, J., Weidmann, E., Maurer, U., Hoelzer, D., Mitrou, P. S., and Bergmann, L. The Wilms' tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR. Ann. Oncol., 6: 811-816, 1995.
68. Menssen, H. D., Renkl, H. J., Rodeck, U., Maurer, J., Notter, M., Schwartz, S., Reinhardt, R., and Thiel, E. Presence of Wilms' tumor gene (WT1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia (Baltimore), 9: 1060-1067, 1995.
69. Menssen, H. D., Renkl, H. J., Rodeck, U., Kari, C., Schwartz, S., and Thiel, E. Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia. Int. J. Cancer, 70: 518-523, 1997.
70. Patmasiriwat, P., Fraizer, G. C., Claxton, D., Kantarjian, H., and Saunders, G. F. Expression pattern of WT1 and GATA-1 in AML with chromosome 16q22 abnormalities. Leukemia (Baltimore), 10: 1127-1133, 1996.
71. Inoue, K., Ogawa, H., Sonoda, Y., Kimura, T., Sakabe, H., Oka, Y., Miyake, S., Tamake, H., Oji, Y., Yamagami, T., Tatekawa, T., Soma, T., Soma, T., Kishimoto, T., and Sugiyama, H. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood, 89: 1405-1412, 1997.
72. Baird, P. N., and Simmons, P. J. Expression of the Wilms' tumor gene (WT1) in normal hematopoiesis. Exp. Hematol., 25: 312-320, 1997.
73. Menssen, H. D., Renkl, H-J., Rodeck, U., Kari, C., Schwartz, S., and Thiel, E. Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia. Int. J. Cancer, 70: 518-523, 1997.
74. Miwa, H., Beran, M., and Saunders, G. F. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia (Baltimore), 6: 405-409, 1992.
75. Miyagi, T., Ahuja, H., Kubota, T., Kubonishi, I., Koeffler, H. P., and Miyoshi, I. Expression of the candidate Wilms' tumor gene, WT1, in human leukemia cells. Leukemia (Baltimore), 7: 970-977, 1993.
76. Brieger, J., Weidmann, E., Fenchel, K., Mitrou, P. S., Hoelzer, D., and Bergmann, L. The expression of the Wilms' tumor gene in acute myelocylic leukemias as a possible marker for leukemic blast cells. Leukemia (Baltimore), 8: 2138-2143, 1994.
77. Inoue, K., Sugiyama, H., Ogawa, H., Nakagawa, M., Yamagami, T., Miwa, H., Kita, K., Hiraoka, A., Masaoka, T., Nasu, K., Kyo, T., Dohy, H., Nakauchi, H., Ishidate, T., Akiyama, T., and Kishimoto, T. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood, 84: 3071-3079, 1994.
78. Patmasiriwat, P., Fraizer, G. C., Claxton, D., Kantarjian, H., and Saunders, G. F. Expression pattern of WT1 and GATA-1 in AML with chromosome 16q22 abnormalities. Leukemia (Baltimore), 10: 1127-1133, 1996.
79. Bergmann, L., Miething, C., Maurer, U., Brieger, J., Karakas, T., Weidmann, E., and Hoelzer, D. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood, 90: 1217-1225, 1997.
80. King-Underwood, L. Renshaw, J., and Pritchard-Jones, K. Mutations in the Wilms' tumor gene WT1 in leukemias. Blood, 87: 2171-2179, 1996.
81. Moffett, P., Bruening, W., Nakagama, H., Bardeesy, D., Housman, D., Housman, E., and Pelletier, J. Antagonism of WT1 activity by protein self-association. Proc. Natl. Acad. Sci. USA, 92: 11105-11109, 1995.
82. Reddy, J. C., Morris, J. C., Wang, J., English, M. A., Luo, X-N., Atweh, F., Haber, D. A., Shi, Y., and Licht, J. D. WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins. J. Biol. Chem., 270: 10878-10884, 1995.
83. Andrews, N. C., and Faller, D. V. A rapid micropreparation technique for extraction of DNA binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res., 19: 2499, 1991.